Patents by Inventor Daniel G. Mullen

Daniel G. Mullen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5858972
    Abstract: The present invention provides antithrombotic agents useful for the management of cardiovascular disease. The agents of the subject invention are novel cyclic peptides encompassed by the following formula:Y-X.sub.1 -X.sub.2 -G-D-X.sub.3 -X.sub.4 -X.sub.5 -Z(SEQ ID NO. 1). In the above formula, X.sub.2 and X.sub.3 are independently a hydrophobic amino acid and X.sub.4 is a positively charged amino acid. The X.sub.1 and X.sub.5 substituents are independently zero to five amino acids. The amino and carboxy terminal amino acids of a given peptide can be modified according to the substituents Y and Z, respectively. The peptides are cyclized through a bridge between the two amino acids with the peptide, excluding G, D and X.sub.3 in the formation of the bridge. Peptides encompassed by the above formula can be administered in a suitable physiologically acceptable carrier to therapeutically treat thrombosis and conditions resulting from the development of thrombi.
    Type: Grant
    Filed: January 11, 1996
    Date of Patent: January 12, 1999
    Assignee: La Jolla Cancer Research Foundation
    Inventors: Michael D. Pierschbacher, Daniel G. Mullen
  • Patent number: 5705609
    Abstract: The present invention provides a method of inhibiting an activity of a cell regulatory factor comprising contacting the cell regulatory factor with a purified polypeptide, wherein the polypeptide comprises a cell regulatory factor binding domain of a protein. The protein is characterized by a leucine-rich repeat of about 24 amino acids. In a specific embodiment, the present invention relates to the ability of decorin, a 40,000 dalton protein that usually carries a glycosaminoglycan chain, and more specifically to active fragments of decorin or its functional equivalents to bind TGF.beta.. The invention also provides a novel cell regulatory factor designated MRF. Also provided are methods of identifying, detecting and purifying cell regulatory factors and proteins which bind and affect the activity of cell regulatory factors.
    Type: Grant
    Filed: May 16, 1995
    Date of Patent: January 6, 1998
    Assignee: La Jolla Cancer Research Foundation
    Inventors: Erkki I. Ruoslahti, Michael D. Pierschbacher, Jose Cardenas, William Craig, Daniel G. Mullen
  • Patent number: 5677276
    Abstract: The present invention provides novel conjugates of a synthetic polypeptide containing RGD or (dR)GD and a biodegradable polymer, hyaluronate. The conjugates are prepared by any one of three different methods provided by the present invention: (1) an epoxide method (2) a sodium periodate method, and (3) a tresyl chloride method. The conjugates prepared by these methods are useful to aid in wound healing and tissue regeneration by providing a temporary matrix for tissue repair. The invention also provides novel RGD-peptides.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: October 14, 1997
    Assignee: La Jolla Cancer Research Foundation
    Inventors: Kenneth T. Dickerson, James R. Glass, Lin-Shu Liu, James W. Polarek, William S. Craig, Daniel G. Mullen, Soan Cheng